IMI Stakeholder Forum 2016 took place in Brussels on 28 – 29 September.
During the first day, the IMI scientific team provided an overview of IMI’s upcoming Call for proposals, to be launched in October 2016.
The call topics presented during this event will cover the following diseases and sectors:
- Unlocking the solute carrier gene-family for effective new therapies
- Precision medicines approaches in autism spectrum disorder
- Improving the care of patients suffering from acute/chronic pain, whose goal is to make advances in three pain areas in a complementary manner. This topic is divided in three subtopics:
- using Patient Reported Outcome Measures to improve the management of acute and chronic pain
- improving the translatability of pharmacodynamic biomarkers in pain pathways of healthy subjects and preclinical species
- improving translation in chronic pelvic pain
- Understanding hypoglycaemia: underlying mechanisms and clinical determinants plus consequences for people with diabetes;
- Enhanced patient voice in medicines lifecycle, whose objectives are to enable patients to better reflect their perspectives in the medicines R&D processes of treatment development;
- Creation of a pan-European paediatric clinical trials network;
- How big data could support better diagnosis and treatment outcomes for prostate cancer;
- Bio-manufacturing 2020: Development of innovative high throughput analytical tools and methods to characterise cell culture fluid during development and commercial culture processes.
The second day was dedicated to different workshops, linked with the topics of IMI Call for proposals:
- Advanced therapies
- Preparedness for emerging diseases
- Digital health
- Oncology
In particular, during the digital health workshop, a panel discussion was dedicated to what patients expect from digital technologies and the influence of the patient’s perspective in the project’s structure.